A clinically relevant large‐scale biomanufacturing workflow to produce natural killer cells and natural killer cell‐derived extracellular vesicles for cancer immunotherapy
Journal of Extracellular Vesicles · 2023
DOI: 10.1002/jev2.12387 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2023. Verfasst von Frederic St-Denis-Bissonnette und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health C…. Hauptthemen laut MEDLINE: Extracellular Vesicles, Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CIHR, Government of Canada, Natural Sciences and Engineering Research Council of Canada.
Abstract (Originalsprache)
Natural killer cell‐derived extracellular vesicles (NK‐EVs) have shown promising potential as biotherapeutics for cancer due to their unique attributes as cytotoxic nanovesicles against cancer cells and immune‐modulatory activity towards immune cells. However, a biomanufacturing workflow is needed to produce clinical‐grade NK‐EVs for pre‐clinical and clinical applications. This study established a novel biomanufacturing workflow using a closed‐loop hollow‐fibre bioreactor to continuously produce NK‐EVs from the clinically relevant NK92‐MI cell line under serum‐free, Xeno‐free and feeder‐free conditions following GMP‐compliant conditions. The NK92 cells grown in the bioreactor for three continuous production lots resulted in large quantities of both NK cell and NK‐EV biotherapeutics at the end of each production lot (over 10 9 viable cells and 10 13 EVs), while retaining their cytotoxic payload (granzyme B and perforin), pro‐inflammatory cytokine (interferon‐gamma) content and cytotoxicity against the human leukemic cell line K562 with limited off‐target toxicity against healthy human fibroblast cells. This scalable biomanufacturing workflow has the potential to facilitate the clinical translation of adoptive NK cell‐based and NK‐EV‐based immunotherapies for cancer with GMP considerations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada, Ottawa, ON, Canada.
- Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
- Centre for Infection, Immunity and Inflammation, University of Ottawa, Ottawa, ON, Canada.
- Ottawa Institute of Systems Biology, University of Ottawa, Ottawa, ON, Canada.
- Kidney Research Centre, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.
ORCID-Profile: Frederic St-Denis-Bissonnette, Jessie R Lavoie
Förderung
- CIHR
- Government of Canada
- Natural Sciences and Engineering Research Council of Canada
- Cancer Research Society
- Canadian Institutes of Health Research
Zitieren
APA
St-Denis-Bissonnette, F., Cummings, S. E., Qiu, S., Stalker, A., Muradia, G., Mehic, J., Mediratta, K., Kaczmarek, S., Burger, D., Lee, S. H., Wang, L., & Lavoie, J. R. (2023). A clinically relevant large‐scale biomanufacturing workflow to produce natural killer cells and natural killer cell‐derived extracellular vesicles for cancer immunotherapy. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.12387
Vancouver
St-Denis-Bissonnette F, Cummings SE, Qiu S, Stalker A, Muradia G, Mehic J, et al. A clinically relevant large‐scale biomanufacturing workflow to produce natural killer cells and natural killer cell‐derived extracellular vesicles for cancer immunotherapy. Journal of Extracellular Vesicles. 2023. doi:10.1002/jev2.12387
BibTeX
@article{StDenisBissonnette2023,
author = {St-Denis-Bissonnette, Frederic and Cummings, Sarah E and Qiu, Shirley and Stalker, Andrew and Muradia, Gauri and Mehic, Jelica and Mediratta, Karan and Kaczmarek, Shelby and Burger, Dylan and Lee, Seung-Hwan and Wang, Lisheng and Lavoie, Jessie R},
title = {A clinically relevant large‐scale biomanufacturing workflow to produce natural killer cells and natural killer cell‐derived extracellular vesicles for cancer immunotherapy},
journal = {Journal of Extracellular Vesicles},
year = {2023},
doi = {10.1002/jev2.12387}
}
EUVIMED